• Aphria Exercises Warrants for Gross Proceeds of $1.3 Million to Further Fund Tetra’s Clinical Trials

    20 March 2017
    0 Views

    Ottawa, Ontario – (Marketwired – March 20, 2017) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE: TBP and OTC: GRPOF) is pleased to announce that Aphria Inc. (TSX-V: APH and USOTCQB: APHQF) has exercised their 5,000,000 warrants for aggregate gross proceeds of $1,300,000. The proceeds from the warrant exercise will be used to advance the clinical trials being developed in PhytoPain Pharma Inc., a subsidiary of Tetra.

    Continue Reading
  • Tetra Bio-Pharma Enters into Binding Term Sheet For Two Products with Panag Pharma

    14 March 2017
    0 Views

    Ottawa, Ontario – (Marketwired – March 14, 2017) –Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), announced today it has entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.

    Continue Reading
  • Tetra Bio-Pharma Announces that the Delay in Legalization of Marijuana Does Not Affect its Drug Development & Commercialization Plans

    9 March 2017
    0 Views

    Ottawa, Ontario – (Marketwired – March 9, 2017) –Tetra Bio-Pharma Inc. (“Tetra”, “TBP” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), a biotechnology company specialized in the development and commercialization of Cannabis-based prescription drugs announced that the delay in legalization of marijuana does not affect its commercialization plans for 2017. AgroTek Health (AGT) for the over-the-counter self-care consumer markets is on schedule for the launch of its first Cannabis-derived (THC- and CBD-free) product in 2017.

    Continue Reading
  • Tetra Bio-Pharma Grants Stock Options

    24 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 24, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF) announces that on February 23, 2017, in accordance with the Company’s stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 750,000 incentive stock options (“options”) to its officers and directors of the Company. Each option, vesting immediately upon grant, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.70 per share until February 23, 2022. The options and any common shares issued upon exercise thereof will be subject to a four month resale restriction from the date of grant.

    Continue Reading
  • Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis)

    23 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9 tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers.

    Continue Reading
  • Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)

    16 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 16, 2017) – PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK: GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

    Continue Reading
  • Tetra Bio-Pharma and IntelGenx Announce the Signing of a Term Sheet for the Development and Commercialization of a Dronabinol XL Tablet

    9 February 2017
    0 Views

    Ottawa, Ontario – (February 9, 2017) – Tetra Bio-Pharma Inc. (“Tetra”) (CSE: TBP) (OTCPINK:GRPOF) and IntelGenx Corp. (“IntelGenx”), (TSXV: IGX) (OTCQX: IGXT), today announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the binding term sheet, Tetra will have exclusive rights to sell the product in North America with a right of first negotiation for outside the U.S. and Canada. The U.S. cancer pain market is expected to reach $5 billion in 2018.

    Continue Reading
  • Tetra Bio-Pharma Inc. Enters into Distribution and Supply Agreement with Engen Medical Corporation

    6 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 6, 2017) – Agro-Tek Inc. (“Agro-Tek”) a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announced today it has entered into an five (5) year exclusive Supply and Distribution agreement with Engen Medical Corporation. (“Engen”) for the Canadian distribution of its Munchies B Gone gum. In exchange for a payment of $28,000 on signing the agreement and a minimum purchase commitment of $1,580,000 over five years, Agro-Tek will have exclusive sales and distribution rights in Canada. Engen will be responsible for all manufacturing and regulatory aspects.

    Continue Reading
  • Tetra Bio-Pharma Inc. Receives Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR Topical Product

    1 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 1, 2017) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP),  a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical Gel Relief (“PPTGR”), being developed as a locally administered therapeutic for the treatment of Chemotherapy-Induced Neuropathic Pain (“CIPN”).

    Continue Reading
  • Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with Food and Drug Administration on PPP001

    30 January 2017
    0 Views

    Ottawa, Ontario – (Marketwired – January 30, 2017) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration (“FDA”) for its PPP001 dried cannabis drug product. The meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (“DAAAP”), Center for Drug Evaluation and Research (“CDER”).

    Continue Reading